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Abstract
Chronic kidney disease (CKD) affects up to 15% of the adult population and is strongly asso-
ciated with other non-communicable chronic diseases including diabetes. However, there is
limited information on a population basis of the relationship between CKD and health-related
quality of life (HRQoL) and the consequent economic cost. We investigated this relationship
in a representative sample in England using the 2010 Health Survey for England. Multivari-
able Tobit models were used to examine the relationship between HRQoL and CKD sever-
ity. HRQoL was converted to quality adjusted life year (QALY) measures by combining
decrements in quality of life with reductions in life expectancy associated with increased dis-
ease severity. QALYs were adjusted for discounting and monetised using the UK threshold
for reimbursement of £30,000. The QALYs were then used in conjunction with forecasted
prevalence to estimate the HRQoL burden associated with CKD among individuals with dia-
betes up to 2025. Individuals with more severe CKD had lower HRQoL compared to those
with better kidney function. Compared to those with normal/low normal kidney function and
stage 1 CKD, those with stage 2, stage 3 with albuminuria and stage 4/5 CKD experienced a
decrement of 0.11, 0.18 and 0.28 in their utility index, respectively. Applying the UK reim-
bursement threshold for a QALY, the monetised lifetime burden of reduced HRQoL due to
stage 2, stage 3 with albuminuria and stage 4/5 CKD were £103,734; £83,399; £125,335 in
males and £143,582; £70,288; £203,804 in females, respectively. Utilizing the predicted
prevalence of CKD among individuals with diabetes mellitus, the economic burden of CKD
per million of individuals with diabetes is forecasted at approximately £11.4 billion in 2025. In
conclusion, CKD has a strong adverse impact on HRQoL in multiple domains. The esti-
mated economic burden of CKD among individuals with diabetes mellitus in the UK is pro-
jected to rise markedly over time.
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Introduction
Chronic kidney disease (CKD) has become a global public health issue whose economic
impact has increased over time [1–3]. It is among the five most common causes of reduced life
expectancy accounting for nearly one million deaths in 2013 [4]. In 2009–2010, the NHS in
England spent approximately £1.45 billion (1.3% their budget) to cover direct and indirect
CKD treatment costs [5], while in the USA, end-stage renal disease treatment costs alone
amounted to $35 billion (6.3% of their annual expenditure) of the Medicare program [6]. The
effects of CKD extend beyond healthcare costs and premature mortality. A systematic review
of patient-reported outcome measures (PROMs) used in CKD supported the use of prefer-
ence-based utility measures, favouring the EuroQoL EQ-5D [7]. Using this a number of stud-
ies have examined the relationship between health-related quality of life (HRQoL) and CKD
demonstrating that those with more severe CKD experience reduced HRQoL [8–17].
While contributing to the literature these papers exhibit a number of limitations. First, as
the impact on HRQoL might legitimately be expected to be greatest among those with more
advanced CKD, many studies omit those with less advanced kidney disease [13–16] and there-
fore do not capture the full burden of CKD. Second, while several studies use multivariable
analyses to control for covariates when estimating the impact of CKD on HRQoL, they adopt
an ordinary least squares (OLS) approach that fails to account for the censored nature of the
HRQoL outcome measure [8,10,11,13,14,17]. Consequently, these studies may produce biased
estimates of the effect of CKD on HRQoL. Third, several studies include among their covari-
ates some co-morbid conditions such as hypertension [8,11] and diabetes [8–13], conditions
that may cause CKD and thus be endogenous to it. This may also result in biased estimates.
In this study, we examine the relationship between HRQoL and CKD among a representa-
tive sample of community dwelling individuals living in England that includes those with
CKD at various levels of severity including none. We use a modelling approach that adjusts for
the censored nature of HRQoL and compare models with and without potentially endogenous
covariates. For illustrative purposes, we estimate the QALY decrement associated with CKD,
value this in monetary terms and using forecasts of disease prevalence, estimate the HRQoL
burden among patients with diabetes related to CKD in the UK up to 2025.
Methods
Data were extracted from the Health Survey for England, an annual survey of community
dwelling adults. Data from the 2010 survey which contained a specific module on measured
kidney function and HRQoL were used [18]. For this study, eligible participants were the 2796
individuals aged over 16 who had a valid serum creatinine value on which CKD could be
staged.
Kidney disease was staged by using the 4-variable MDRD estimated glomerular filtration
rate (eGFR) equation and albuminuria quantified by a spot urinary albumin/creatinine ratio
(ACR). Participants were categorised into one of seven groups: normal (eGFR>90 ml/min/
1.73m2 and normal albuminuria), low normal (eGFR>60&<90 and normal albuminuria),
stage 1 CKD (eGFR�90 and micro or macro albuminuria), stage 2 CKD (eGFR>60&<90
and micro or macro albuminuria), stage 3 CKD without albuminuria (eGFR >30&<60 and
normal albuminuria), stage 3 CKD with albuminuria (eGFR >30&<60 and micro or macro
albuminuria), and stage 4/5 CKD (eGFR<30 regardless of albuminuria). Micro albuminuria
(higher urinary albumin excretion) and macro albuminuria (very high urinary albumin excre-
tion) were based on an ACR of 30–300 mg/mmol and >300 mg/mmol respectively.
The EuroQoL EQ-5D-3L instrument was used to elicit self-reported health. Health states
were described across five domains: mobility, self-care, usual activities, pain/discomfort and
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anxiety/depression at three levels of severity [18]. The eq5d command was used to convert self-
reported health into a preference weight using the English value set [19].
Sociodemographic characteristics shown to impact on quality of life (QoL) among individ-
uals with CKD were extracted for inclusion in the analysis. These included age [8,9,11,14,16],
gender [8–11,13,16], religiosity [15,16], location [15], ethnicity [13,14], education level [8,16],
marital status [8,16], and income [8]. In this study, sociodemographic variables comprised
equivalised household income, age (less than 50 years old and 50 years old and older), gender
(male and female), marital status (single and married/civil partnership), education (less than
19 years of education and 19 years or more of education), ethnicity (White British and other
ethnicities), religion (no religion and have religion), location (urban area and rural area).
Equivalised household income was calculated by dividing the total income of a household in
the 12-month period preceding the survey (after tax and other deductions) by the converted
number of household members. The household members were converted into equalised adults
using the modified OECD (Organisation for Economic Co-operation and Development)
equivalence scale [20]. Equivalised household income was then converted to Quintiles: Highest
Quintile (>£45,138.89), Second highest Quintile (>£29,166.67 &�£45,138.89), Middle Quin-
tile (>£19,090.91 &�£29,166.67), Second lowest Quintile (>£11,142.86 &�£19,090.91) and
Lowest Quintile (�£11,142.86).
Data analysis
Participant characteristics were compared between different kidney disease status using χ2
tests for categorical variables. Descriptive statistics were used to describe kidney disease status
among groups stratified by age, gender, socio-economic status, marital status and ethnicity.
A series of multivariable Tobit models in which kidney disease and sociodemographic char-
acteristics were regressed on utility scores were estimated. The relationship between kidney
disease and specific domains of health captured in the EQ-5D were analysed using ordered
Probit models controlling for the same covariates.
As hypertension and diabetes are the two most common comorbidities associated with
CKD [8–13], we conducted sensitivity analyses in which these were included as well as omitted
as regressors. We also estimated a saturated model that included all identified health condi-
tions in HSE 2010 (including: neoplasms, endocrine and metabolic, mental disorders, nervous
system, eye complaints, ear complaints, heart and circulatory system, respiratory system,
digestive system, genitourinary system, skin complaints, musculoskeletal system, infectious
disease and blood and related organs issue) as covariates.
We weighted the sample for nurse-based measures to account for representativeness. This
weighted tool was provided by HSE 2010, taking into account the non-response to nurse sec-
tion from respondents. All P-values were 2-sided with alpha = 0.05 as the threshold for statisti-
cal significance.
Projected burden
The median age of each CKD group was estimated from the data for males and females. Life
expectancy by age group and gender were based on Turin et al [21]. As HRQoL might be
expected to deteriorate with age, the decrement in utility related to CKD was adjusted to take
account of each CKD age group using Ara et al [22]. The QALY decrement associated with
CKD was based on the reduction in life expectancy and reduction in HRQoL between those
with CKD at a given stage and those without. A discount rate of 3.5% consistent with that rec-
ommended by NICE [23] was applied to years experienced in the future and the result was
monetised using the NICE threshold willingness to pay for a QALY of £30,000. The monetised
Chronic kidney disease and health-related quality of life in England
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value of QALYs loss was extrapolated using estimates for the prevalence of CKD by stage
among individuals with diabetes to forecast the HRQoL loss in monetary terms for CKD in a
population with diabetes up to 2025 [24]. Full details are set out in the supplementary file.
Results
Descriptive statistic
The characteristics of respondents are shown in Table 1. The Normal and Low normal catego-
ries were combined to Normal/Low normal GFR group in the interests of parsimony while
Table 1. Demographic characteristics, socioeconomic status and comorbidities of participants stratified to eGFR level.
Normal/Low
normal GFR
n = 2,439
Stage 1 CKD
n = 56
Stage 2 CKD
n = 106
Stage 3 CKD
(Without
albuminuria)
n = 155
Stage 3 CKD
(With
albuminuria)
n = 35
Stage 4/5 CKD
n = 5
P-value
N % N % N % N % N % N %
Age (Mean, SD) 48.7 15.9 44.6 18.2 60.0 17.4 65.3 14.8 74.1 13.4 72.2 10.3 p < 0.001
Age p < 0.001
< 50 years old 1,298 53.2% 33 58.9% 30 28.3% 26 16.8% 3 8.6% 0 0.0%
� 50 years old 1,141 46.8% 23 41.1% 76 71.7% 129 83.2% 32 91.4% 5 100.0%
Gender P = 0.003
Male 1,084 44.4% 19 33.9% 53 50.0% 72 46.5% 21 60.0% 2 40.0%
Female 1,355 55.6% 37 66.1% 53 50.0% 83 53.6% 14 40.0% 3 60.0%
Income p < 0.001
� £11,142.86 331 13.6% 16 28.6% 22 20.8% 21 13.6% 5 14.3% 1 20.0%
>£11,142.86�£19,090.91 406 16.7% 7 12.5% 17 16.0% 29 18.7% 11 31.4% 0 0.0%
>£19,090.91�£29,166.67 504 20.7% 14 25.0% 27 25.5% 50 32.3% 10 28.6% 2 40.0%
>£29,166.67�£45,138.89 572 23.5% 11 19.6% 25 23.6% 28 18.1% 7 20.0% 2 40.0%
>£45,138.89 626 25.7% 8 14.3% 15 14.2% 27 17.4% 2 5.7% 0 0.0%
Marital status p < 0.001
Single 1,000 41.0% 29 51.8% 45 42.5% 75 48.4% 12 34.3% 2 40.0%
Married/ Civil partnership 1,439 59.0% 27 48.2% 61 57.6% 80 51.6% 23 65.7% 3 60.0%
Ethnicity p < 0.001
White British 2,207 90.5% 49 87.5% 96 90.6% 142 91.6% 33 94.3% 5 100.0%
Other ethnicities 232 9.5% 7 12.5% 10 9.4% 13 8.4% 2 5.7% 0 0.0%
Location p < 0.001
Urban area 2,115 86.7% 48 85.7% 91 85.9% 138 89.0% 29 82.9% 5 100.0%
Rural area 324 13.3% 8 14.3% 15 14.2% 17 11.0% 6 17.1% 0 0.0%
Religion p < 0.001
No religion 1,797 73.7% 48 85.7% 84 79.3% 131 84.5% 30 85.7% 3 60.0%
Have religion 642 26.3% 8 14.3% 22 20.8% 24 15.5% 5 14.3% 2 40.0%
Education p < 0.001
< 19 years 1,757 72.0% 43 76.8% 81 76.4% 127 81.9% 32 91.4% 3 60.0%
� 19 years 682 28.0% 13 23.2% 25 23.6% 28 18.1% 3 8.6% 2 40.0%
Diabetes p < 0.001
No 2,338 95.9% 49 87.5% 92 86.8% 139 89.7% 28 80.0% 3 60.0%
Yes 101 4.1% 7 12.5% 14 13.2% 16 10.3% 7 20.0% 2 40.0%
Hypertension p < 0.001
No 1,499 71.6% 26 52.0% 41 44.6% 65 44.5% 9 29.0% 0 0.0%
Yes 595 28.4% 24 48.0% 51 55.4% 81 55.5% 22 71.0% 3 100.0%
https://doi.org/10.1371/journal.pone.0207960.t001
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allowing for the comparison between normal kidney function and other CKD levels. The mean
age of the normal/low normal GFR group was 48.7 years old (±15.9). The mean age of partici-
pants increased with the severity of CKD, from 44.6 (±18.2) in stage 1 CKD to 74.1 (±13.4) in
stage 3 CKD with albuminuria. A majority of the respondents were female, with the exception
of stage 3 CKD with albuminuria where there were more males (60%) than females (40%). Most
people in the normal/low normal eGFR groups were in the highest quintiles of income, the
majority of respondents with CKD at other stages were in the lower income quintiles. Most par-
ticipants were married, White British, living in an urban area and having no religion. Except for
stage 4/5 CKD, the education level decreased with the severity of CKD, from 28% having more
than 19 years of education in normal/low normal kidney function group to 8.6% of those in
stage 3 CKD with albuminuria. Regarding comorbidities, one fifth of patients with stage 3 CKD
and albuminuria had diabetes and two thirds of those with stage 4/5 CKD had diabetes. The
proportion of respondents with hypertension increased with the severity of CKD, ranging from
28.4% (normal/low normal kidney function) to 100% (stage 4/5). In general, the older, less well-
educated and poorer respondents were more likely to have reduced kidney function.
The proportions of respondents reporting any problems to the EQ-5D questionnaire are
presented in Fig 1. In general, respondents seemed to report more problems in pain/discom-
fort and anxiety/depression domains than in usual activity, mobility and self-care domains.
The proportion of those answering “No problems” was 83.6%, 96%, 84.9%, 65% and 77.8% in
mobility, self-care, usual activity, pain/discomfort and anxiety/depression, respectively. In all
stages of CKD, the pain/discomfort domain captured the highest proportion of people report-
ing the second level in three levels of EQ-5D-3L questionnaire, which were 30.3%, 32.1%,
43.4%, 43.2% and 51.4% in normal/low normal eGFR, stage 1, stage 2, stage 3 without albu-
minuria, stage 3 with albuminuria and stage 4/5 CKD, respectively. Fewer than 8.6% of the
respondents reported ‘‘Extreme problem” for all dimensions.
In the base case model, a significant decrement of 0.11, 0.18 and 0.28 in health utility index
was experienced by individuals with stage 2, stage 3 with albuminuria and stage 4/5 CKD com-
pared to those with normal/low normal kidney function and stage 1 CKD, after adjustment
for the other covariates. For sociodemographic data, people who were married and had more
than 19 years of education had a better QoL than the comparator groups. Higher income was
associated with better reported QoL. Compared to the lowest equivalised income quintiles
(�£11,142.86 per year), people with Second lowest Quintile (>£11,142.86 &�£19,090.91),
Fig 1. The proportion of respondents reporting any problems in each domain of EQ-5D questionnaire. Note:
Stage 3(i): Stage 3 CKD with albuminuria, Stage 3(ii): Stage 3 CKD without albuminuria.
https://doi.org/10.1371/journal.pone.0207960.g001
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Middle Quintile (>£19,090.91 &�£29,166.67), Second highest Quintile (>£29,166.67 &
�£45,138.89) and Highest Quintile (>£45,138.89) had significantly higher health utility indi-
ces of 0.08, 0.16, 0.20, 0.21, respectively. Females and people aged over 50 had worse health sta-
tus with a decrement of 0.05 and 0.16 compared to male and those under 50 years old (Fig 2).
Sensitivity analysis
The results of the sensitivity analyses are shown in supplementary document (S1 Table). When
repeating the analysis using three sets of possible endogenous comorbidities (diabetes; hyper-
tension; diabetes and hypertension), CKD continued to have a significant independent impact
on HRQoL though its effect was attenuated and the coefficient of stage 4/5 CKD was no longer
significant in the model including both diabetes and hypertension (-0.212, 95% CI: -0.451,
0.027). In the saturated models, CKD status continued to significantly and independently pre-
dict HRQoL though again its effect was attenuated. (S1 Fig and S2 Fig in the supplement pres-
ent these results.)
Exploring the relationship between CKD status and specific domains of
health in EQ-5D
In Table 2, the results of the ordered logistic regressions examining the relationships between
specific domains of health and CKD stage are presented in the form of estimated average mar-
ginal effects. As the coefficients in nonlinear models are not intuitively meaningful, marginal
effects are another popular means to present results [25]. In brief while the presence and sever-
ity of CKD was related to problems with mobility, usual activity and pain/discomfort, no sig-
nificant relationship was found in the self-care and anxiety/depression domains. Patients in
stage 4/5 CKD, were respectively 59.5%, 38.7%, 36.3% points less likely to report “no
Fig 2. Multivariable Tobit model exploring the relationship between CKD severity and HRQoL (the base case
model). Note: †: Income2 (>£11,142.86 &�£19,090.91), Income3 (>£19,090.91 &�£29,166.67), Income4
(>£29,166.67 &�£45,138.89), Income5 (>£45,138.89); (i) Stage 3 CKD without albuminuria, (ii) Stage 3 CKD with
albuminuria. Bar represents 95% Confidence Intervals (CI), Dot represents the coefficient of the multivariable Tobit
model.
https://doi.org/10.1371/journal.pone.0207960.g002
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problems” in mobility, usual activity and pain/discomfort compared to those with normal/low
normal kidney function and stage 1 CKD. However, there were significant 52.1%, 27.4%,
25.4% points increases in the probability of reporting “some problems” in these three domains.
The probabilities of reporting “extreme problems” was 7.4% and 10.9% points in mobility and
pain/discomfort domains. Similarly, individuals with stage 3 CKD with albuminuria were less
likely to report “no problems” and more likely to report “some problems” in mobility and
usual activity. For individuals with less severe kidney disease, respondents with stage 2 CKD
were also less likely to report “no problems” and more likely to report “some problems” or
“extreme problems” in mobility and pain/discomfort domain of health.
The burden of chronic kidney disease and projections among those with
diabetes to 2025
Using the base case model (Model 1) to project the economic burden of CKD to 2025, the
QALY decrement between patients with CKD and individuals from a healthy population at
the same age showed significant differences. In males, those with stage 2, stage 3 with albumin-
uria and stage 4/5 CKD suffered a loss of 3.5, 2.8 and 4.2 QALY, respectively. In females, stage
2, stage 3 with albuminuria and stage 4/5 CKD are associated with a loss of 4.8, 2.3 and 6.8
QALY, respectively. Applying a reimbursement threshold of £30,000 per QALY in the UK set-
ting, the monetised burden of reduced HRQoL due to stage 2, stage 3 with albuminuria and
Table 2. Estimated marginal effects.
EQ-5D domain Stage 2 CKD Stage 3 CKD
(without albuminuria)
Stage 3 CKD
(with albuminuria)
Stage 4/5 CKD
Mobility
No problems -0.070� -0.063 -0.180� -0.595��
Some problems 0.069� 0.061 0.175� 0.521��
Confined to bed 0.001 0.001 0.005 0.074�
Self-care
No problems -0.033 -0.006 -0.066 -0.097
Some problems 0.031 0.006 0.062 0.090
Unable to wash/dress 0.002 0.000 0.004 0.007
Usual activity
No problems -0.036 -0.048 -0.183� -0.387�
Some problems 0.031 0.041 0.148� 0.274��
Unable to perform usual activity 0.005 0.007 0.035� 0.112
Pain/discomfort
No pain or discomfort -0.115� -0.076 -0.135 -0.363��
Moderate pain or discomfort 0.096� 0.064 0.111 0.254��
Extreme pain or discomfort 0.019� 0.012 0.024 0.109��
Anxiety/Depression
Not anxious or depressed -0.041 -0.002 -0.012 0.041
Moderately anxious or depressed 0.035 0.002 0.011 -0.036
Extremely anxious or depressed 0.006 0.000 0.002 -0.005
The dependent variables (Mobility, Self-care, Usual activity, Pain/discomfort, Anxiety/Depression) are ordered variables taking values of no problems, some problems
and extreme problems. We used the ordered Probit model, adjusted for equivalised household income, age, gender, marital status, education level, ethnicity, religion
and location. All models were appropriately weighted for the sample.
�Denotes significant at 5%
��Denotes significant at 1%.
https://doi.org/10.1371/journal.pone.0207960.t002
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stage 4/5 CKD were £103,734; £83,399; £125,335 in males and £143,582; £70,288; £203,804 in
females, respectively. Extrapolating these out to 2025, per million of persons with diabetes in
the UK, the present value of QALYs lost associated with CKD stages 3–5 will be approximately
£11.4 billion (95% CI: 9.1, 14.4) of which 55% will be in women and 45% will be in men (Fig
3). The allocated proportion for stage 3, stage 4 and stage 5 CKD will be 79%, 15% and 6% of
the total burden. Full details in the breakdown by gender and stage are presented in the supple-
ment (S3 Fig).
Discussion
Our study shows a clear decrement in HRQoL associated with CKD. The finding is consistent
with previous studies that focused on those with established disease regardless of the instruments
used to measure QoL [8–12,17,26]. After adjustment for other covariates in the ordered Probit
models, mobility, usual activity and pain/discomfort were three dimensions of health that were
more likely related to CKD; in which pain/discomfort showed a more significant marginal effect
on the HRQoL. This finding is consistent with a study from Lee et al. (2012) in which mobility
and pain/discomfort were the domains largely affected [8]. Unfortunately, chronic pain has not
been considered a major problem in individuals with CKD to date [27]. We found that, consis-
tent with other studies, having a higher income [8], being married [8,16], having better educa-
tion [8,16], being younger [8,11] and male [8–11] were all associated with higher levels of
HRQoL. Conversely, Yang et al. (2015) reported that older patients had better QoL than younger
patients which might be due to the older sample used in that study (aged 60 and over) and the
potential adaptation to chronic conditions and adjustment of expectations [14].
Our illustrative estimate underscores the magnitude of the HRQoL burden associated with
CKD when expressed in monetary terms. Per person the lifetime HRQoL of CKD was
£103,734; £83,399; £125,335 in males and £143,582; £70,288; £203,804 in females with stage 2,
stage 3 with albuminuria and stage 4/5 CKD, respectively. Extrapolating these figures to reflect
the growing prevalence of diabetes and CKD among individuals with diabetes further
Fig 3. Projected economic burden of stages 3–5 CKD from 2012 up to 2025 in the UK. pmp: per million diabetic
population. Line represents the prediction economic burden per million diabetic population from 2012 up to 2025; the
dark area represents 95% Confidence Intervals (CI).
https://doi.org/10.1371/journal.pone.0207960.g003
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highlights the magnitude of the issue. Extrapolating the lifetime monetised value to the popula-
tion the lost HRQoL is equivalent to £7.18 billion (£3.18 billion for males and £3.90 billion for
females) in 2012, a figure we have shown seems destined to increase with the prevalence of dia-
betes in the short to medium term. Despite the significant burden in terms of HRQoL, CKD
continues to be allocated a meagre share of research resources according to the budget expen-
diture report of the Centers for Disease Control and Prevention [28]. In addition, CKD aware-
ness remains extremely low in both high-income and low and middle-income countries [29],
this lack of awareness undermining the development of a more appropriate policy response in
terms of the provision for services, the promotion of effective prevention and education ser-
vices, and the priority afforded research in this area. Based on our findings clearly a reappraisal
of the priority attached CKD is warranted.
Strengths
This is the first population-based analysis of the relationship between CKD and HRQoL using
the preference based EQ-5D utility in the UK. While most of other studies focused on moder-
ate to severe CKD or ESRD, our study investigated the HRQoL in all stages of CKD.
This is also the first study to monetise the QALY loss due to kidney impairment in each
CKD stage, whilst controlling for a range of covariates, and extrapolates this value to forecast
the burden for DKD up to 2025.
In order to capture the censored nature of health utility index, we applied a set of multivari-
able Tobit models as this type of model has been widely used in this specific type of data and is
better suited to the analysis of censored data than ordinary least squares [20]. We also investi-
gated the impact of hypertension and diabetes as potential endogenous regressors of CKD in
explaining the decrement in health utility.
Limitations
We used HSE 2010 data, which though the most recent year for which data is available is now
some 8 years out of date. We use cross sectional data that examines associations rather than
causal relationships, again though in the absence of large follow-up studies this is a restriction
imposed on us. This is similarly the case with respect to the use of EQ-5D-3L which is known
to be less sensitive and to be more likely to suffer ceiling effects compared to the 5L or disease
specific QoL measures. This again however, was a restriction imposed on us by the data.
There is also the uncertainty in the estimated economic burden as this work was based on
another study to obtain the projected prevalence of CKD per million diabetes population up to
2025. However, we obtained the 95% CI of the estimates from a study of Kainz et al. whilst still
recognising the inherent uncertainty in any kind of projection [24]. This is similarly the case
with the use of estimated life expectancy.
There are also pitfalls in methods to estimate eGFR and classify CKD. In HSE 2010, CKD
was classified using the estimated glomerular filtration measures (eGFR) obtained from
MDRD equation [5,30]. While the CKD-EPI equation could provide more accurate estimates
than MDRD equation, it was also reported that the global prevalence of CKD may have been
overestimated by>50% due to the cumulative impact of pitfalls in prevalence estimates based
on these two equations [31]. Moreover, false positive test results while screening and monitor-
ing CKD has been a common issue and could affect the QoL of patients [32]. However, this
issue is related to the standard technique and equation to estimate eGFR value and need fur-
ther studies to address.
The small number of observations in persons with stage 4/5 CKD will inevitably increase
uncertainty around estimates for more severe disease. However, as more severe disease is less
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prevalent in the population, this is an inevitable compromise associated with the use of a popu-
lation-based survey. Only by increasing substantially the sample size–a matter beyond our
control—could this be addressed.
Conclusion
The severity of CKD predicts self-reported HRQoL. We found that as CKD severity increased
so the HRQoL fell in a manner consistent with intuition. Using estimated life expectancy,
CKD prevalence forecasts and the reimbursement threshold used in the UK for the valuation
of QALYs, we estimated the HRQoL burden of CKD per million of the population with diabe-
tes to rise from £7.08 billion to £11.4 billion between 2012 and 2025 in the UK.
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